First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. - Wikidata - wikimedia - TriplyDB

First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.

First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.

http://www.wikidata.org/entity/Q33420907

about

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor

P2860

Q26738509-3F0676B6-A9BB-40EA-A958-4E21D574AA30 Q27004054-B7101246-CC27-4DE5-898F-A11E4D1D4A17

P2860

First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.

http://www.wikidata.org/entity/Q33420907

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

First-in-human, phase I/IIa do ...... myelosuppressive chemotherapy.

@ast

First-in-human, phase I/IIa do ...... myelosuppressive chemotherapy.

@en

type

label

First-in-human, phase I/IIa do ...... myelosuppressive chemotherapy.

@ast

First-in-human, phase I/IIa do ...... myelosuppressive chemotherapy.

@en

prefLabel

First-in-human, phase I/IIa do ...... myelosuppressive chemotherapy.

@ast

First-in-human, phase I/IIa do ...... myelosuppressive chemotherapy.

@en

P1433

Q33420907-4E876B0C-485F-46C8-BCCA-8878104E162D

P1476

Q33420907-58D1303E-6B86-4A7D-B4A3-33AD40A9F027

P2093

Q33420907-4DEA5148-0B02-4AC0-B977-D0AAD8B0AB4A

Q33420907-795FE464-F0BF-4575-B236-673FC9D2EDB2

Q33420907-8FF738FC-BC3D-4F84-97CC-AA9D962A4257

Q33420907-DD2BA2E2-C178-47BF-9EBC-E3CE9521F201

Q33420907-E88E2C14-A593-43A1-A909-A6979574E447

Q33420907-EDE6BB2C-BCDF-43A3-AA6A-12607A221899

Q33420907-FCE305E0-F8E1-482C-AC6A-306214C94B09

P2860

Q33420907-02DF99A8-3589-4E51-A495-97DE7181C9D4

Q33420907-2BA76732-10E0-4D9B-8917-DD09EAEDF69B

Q33420907-48B64337-3BFA-4872-9997-AF041A1CD601

Q33420907-55062679-6DF3-4A05-A339-9EF225A376E9

Q33420907-7228B9F5-3580-416E-8205-7DAFE27A0EC1

Q33420907-78D0CF67-D65F-4EA7-BDA0-5D090D3A21AB

Q33420907-B733A8B1-2AAD-40A8-9DD2-3ACF7AA632D1

Q33420907-C4ED6CBC-0E6D-4D3A-BCB4-73507E44E56E

Q33420907-E9098CCB-ABB8-48D5-8F3E-2A44F1622E8E

Q33420907-EB1598D6-F151-4065-B5D0-B65E48B20083

P2888

Q33420907-1A6B2430-4BAA-4F24-A05F-49E7A7A5C747

P304

Q33420907-6FBC5822-E113-44A6-8040-7881846D4125

P31

Q33420907-FAB837DA-C32E-4947-A0EE-70C0CB659B56

P356

Q33420907-492E73D0-027B-4DA5-94A6-F491E2F7D75B

P433

Q33420907-94F91F18-D399-4833-9572-2C5FA5423096

P478

Q33420907-176AB144-B28A-4490-987D-723624980BD8

P577

Q33420907-659603DF-45B3-48D3-BAFE-B240AA83764E

P6179

Q33420907-BD8AC3A3-FF19-48F8-8F8D-FCB2EE3C0846

P698

Q33420907-07D0C6D8-EEAB-4EBE-A6A1-9F67176D4340

P356

S00280-015-2703-1

P1433

Cancer Chemotherapy and Pharmacology

P1476

First-in-human, phase I/IIa do ...... myelosuppressive chemotherapy.

@en

P2093

David Shen

http://www.w3.org/2001/XMLSchema#string

Jason Bock

http://www.w3.org/2001/XMLSchema#string

Laurie Pukac

http://www.w3.org/2001/XMLSchema#string

Liat Adar

http://www.w3.org/2001/XMLSchema#string

Noa Avisar

http://www.w3.org/2001/XMLSchema#string

Steve Barash

http://www.w3.org/2001/XMLSchema#string

Udo Müller

http://www.w3.org/2001/XMLSchema#string

P2860

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Impact of albumin on drug delivery--new applications on the horizon.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

G-CSF: a key regulator of neutrophil production, but that's not all!

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

Pharmacokinetics and pharmacodynamics of pegfilgrastim.

Chemotherapy regimens in early breast cancer: major controversies and future outlook.

Albumin as a versatile platform for drug half-life extension.

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

P2888

s00280-015-2703-1

P304

929-939

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-015-2703-1

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1034581713

http://www.w3.org/2001/XMLSchema#string

P698

25740691

http://www.w3.org/2001/XMLSchema#string